Health Economics›Mantle cell lymphoma›First-line therapy

First-line therapy

Mantle cell lymphoma · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FCR Variant #07	—	R 120 349	30d	—	44.5 mo	5	R 361 047 PFS proxy	1
Cyclophosphamide and Fludarabine (FC) Variant #15	—	R 14 005	—	—	37.0 mo	8	R 112 036 PFS proxy	1
MCP Variant #01	—	R 6 850	28d	—	—	~8	~R 54 799 indirect	—
VAD+C Variant #01	—	R 3 240	35d	—	—	~8	~R 25 919 indirect	—
CHOP Variant #20	—	R 835	21d	—	—	~6	~R 5 011 PFS proxy · indirect	1

5 of 5 regimens shown